- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2022
- 37 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Intermittent Claudication (IC) is a type of cardiovascular disease caused by a narrowing of the arteries in the legs. It is characterized by pain in the legs during physical activity, such as walking, which is relieved by rest. Treatment for IC typically involves lifestyle changes, such as quitting smoking and exercising regularly, as well as medications to reduce inflammation and improve blood flow. Commonly prescribed drugs for IC include statins, antiplatelet agents, and anticoagulants.
The Intermittent Claudication Drug market is a subset of the larger Cardiovascular Drugs market. It is composed of pharmaceutical companies that develop and market drugs to treat IC. These companies are typically involved in research and development, manufacturing, and marketing of IC drugs.
Some companies in the Intermittent Claudication Drug market include Pfizer, Merck, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more